4598 — Delta-Fly Pharma Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Delta-Fly Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 300 | 300 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,152 | 1,261 | 1,316 | 1,403 | 1,708 |
| Operating Profit | -852 | -961 | -1,316 | -1,403 | -1,708 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -859 | -964 | -1,326 | -1,427 | -1,719 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -863 | -967 | -1,329 | -1,429 | -1,721 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -863 | -967 | -1,329 | -1,429 | -1,721 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -863 | -967 | -1,329 | -1,429 | -1,721 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -187 | -179 | -235 | -199 | -196 |
| Dividends per Share |